255 related articles for article (PubMed ID: 28220447)
1. Current Management of Refractory Germ Cell Tumors and Future Directions.
Allen JC; Kirschner A; Scarpato KR; Morgans AK
Curr Oncol Rep; 2017 Feb; 19(2):8. PubMed ID: 28220447
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
3. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic approaches for refractory germ cell cancer.
Oing C; Seidel C; Bokemeyer C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):389-397. PubMed ID: 29516750
[TBL] [Abstract][Full Text] [Related]
5. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
Kozakova K; Mego M; Cheng L; Chovanec M
Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
[TBL] [Abstract][Full Text] [Related]
6. Targeted treatment approaches in refractory germ cell tumors.
Galvez-Carvajal L; Sanchez-Muñoz A; Ribelles N; Saez M; Baena J; Ruiz S; Ithurbisquy C; Alba E
Crit Rev Oncol Hematol; 2019 Nov; 143():130-138. PubMed ID: 31634730
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.
Mandanas RA; Saez RA; Epstein RB; Confer DL; Selby GB
Bone Marrow Transplant; 1998 Mar; 21(6):569-76. PubMed ID: 9543060
[TBL] [Abstract][Full Text] [Related]
8. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
[TBL] [Abstract][Full Text] [Related]
9. Current Management of Refractory Germ Cell Tumors.
Abughanimeh O; Teply BA
Curr Oncol Rep; 2021 Jul; 23(9):101. PubMed ID: 34269906
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
11. Investigational targeted therapies for the treatment of testicular germ cell tumors.
Oing C; Kollmannsberger C; Oechsle K; Bokemeyer C
Expert Opin Investig Drugs; 2016 Sep; 25(9):1033-43. PubMed ID: 27286362
[TBL] [Abstract][Full Text] [Related]
12. Emerging Therapeutic Targets for Male Germ Cell Tumors.
Fankhauser CD; Honecker F; Beyer J; Bode PK
Curr Oncol Rep; 2015 Dec; 17(12):54. PubMed ID: 26449842
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
14. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer.
Kawai K; Akaza H
Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Kollmannsberger C; Nichols C; Bokemeyer C
Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
Hartmann JT; Einhorn L; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Bokemeyer C
J Clin Oncol; 2001 Mar; 19(6):1641-8. PubMed ID: 11250992
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
Semaan A; Haddad FG; Eid R; Kourie HR; Nemr E
Future Oncol; 2019 Feb; 15(5):533-541. PubMed ID: 30624089
[TBL] [Abstract][Full Text] [Related]
19. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
[TBL] [Abstract][Full Text] [Related]
20. Platinum-refractory germ cell tumors: an update on current treatment options and developments.
Oing C; Alsdorf WH; von Amsberg G; Oechsle K; Bokemeyer C
World J Urol; 2017 Aug; 35(8):1167-1175. PubMed ID: 27449639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]